carisma c ardiac a rrhythmias and ri sk s tratification after m yocardial inf a rction

21
Long-term Cardiac Arrhythmias recorded by an Insertable Loop Recorder in Patients with Depressed Left Ventricular Function after Acute Myocardial Infarction CARISMA Cardiac Arrhythmias and RIsk Stratification after Myocardial infArction PE Bloch Thomsen,MD,PhD Gentofte University Hospital Copenhagen, Denmark pebt@ geh.regionh.dk

Upload: feo

Post on 13-Jan-2016

20 views

Category:

Documents


0 download

DESCRIPTION

Long-term Cardiac Arrhythmias recorded by an Insertable Loop Recorder in Patients with Depressed Left Ventricular Function after Acute Myocardial Infarction. CARISMA C ardiac A rrhythmias and RI sk S tratification after M yocardial inf A rction. PE Bloch Thomsen,MD,PhD - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Long-term Cardiac Arrhythmias recorded by an Insertable Loop Recorder in Patients with

Depressed Left Ventricular Function after Acute Myocardial Infarction

CARISMACardiac Arrhythmias and RIsk Stratification after Myocardial infArction

PE Bloch Thomsen,MD,PhD Gentofte University Hospital

Copenhagen, Denmarkpebt@ geh.regionh.dk

Page 2: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

CARISMA investigators

Principal investigators: H. Huikuri, Finland, PE Bloch Thomsen, Denmark

P. Raatikainen University of Oulu, FinlandR.M. Joergensen University of Copenhagen, Denmark J. Hartikainen University of Kuopio, FinlandV. Virtanen University of Tampere, FinlandJ. Boland Hopital Citadelle, Liège, BelgiumO. Anttonen Paijat-Hame Hospital, Lahti, FinlandL.A.V. Boersma St. Antonius Hospital, Nieuwegein,

NetherlandsE.S. Platou University of Oslo, NorwayE. Stoupel Hopital Erasme, Brussels, BelgiumJ. Rokkedal, N. Hoest Amtssygehuset Glostrup, Denmark

European multicenter, prospective, observational study

Page 3: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Disclosures

Research grant and speaker fee • Boston Scientific Guidant

• Medtronic BRC • St. Jude Medical

CARISMA was sponsored by

• Medtronic Bakken Research Center

• Cambridge Heart Inc

Page 4: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Assess the predictive value of

electrophysiologic testing and

non-invasive screening tests for

life-threatening tachyarrhythmias in

patients surviving AMI with EF ≤ 0.40

CARISMA – Objective 1

(HRS, Hot Line Session, Denver, May 10, 2007)

Page 5: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

CARISMA – Objective 2

Document the incidence and assess

the prognostic significance of cardiac

arrhythmias obtained from an

implantable ECG loop recorder

Page 6: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Implantable loop recorder

Weight 1/2 oz, 8 cc. Longevity up to 2 years. ECG storage 42 min, automatic arrhythmia detection algorithms

Sampling rate 100 Hz

Page 7: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Inclusion criteria

• Patients within 3 to 21 days of AMI + CKMB or Troponin elevation+ Typical chest pain or ECG changes

• EF ≤ 40%, 2-D echo ( WMI ≤ 1.3)

• Planned CABG/ ICD • NYHA IV• Informed consent not obtained

Exclusion criteria

Page 8: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Study design

312 pts

informed consent

1393 (24%) EF ≤ 40%

5869 pts with AMI

ILR implantation

297 pts

5-21 dayspost-MI

3-21 dayspost-MI

Quarterly follow-up 2 yearpost-MI

Page 9: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Patient characteristics Enrollment: 2002-2005

Baseline# of pts 312Gender (men) 77%Age (years) 65

11LVEF 31%

6 AFib permanent 9%QRS > 120 ms 15%Diabetes 20%Prior MI 37%Hx of CHF (II-III) 11%

RevascularizationPrimary PCI 30%

Thrombolysis 35%

Rx at dischargeASA 90%

Beta-blockers 96%

ACE / AT II 89%

Statins 82%

Page 10: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Definitions Pre-specified arrhythmia

Sinus bradycardia ≤ 30 bpm, ≥ 8s

Sinus arrest ≥ 5s

AV block (2°, 3°) ≤ 30 bpm, ≥ 8s

Non-sustained VT ≥ 125 bpm, ≥16 beats

Sustained VT ≥ 125 bpm, ≥30s

AFib ≥ 125 bpm

Page 11: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Incidence of arrhythmias recorded by the ILR

Mean follow-up 1.9 years

137 pts (46%) documented at least one of the pre-specified arrhythmias

86% were asymptomatic

Page 12: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Bradyarrhythmia: Time to first arrhythmia by ILR

1.0

0.7

0.8

0.9

0.0

0 200 400 600 800

Time (days)

Eve

nts

Fre

e

1.0

0.7

0.8

0.9

0.0

0 200 400 600 800

Time (days)

Eve

nts

Fre

e

S. ArrestS. BradyAV block

Sinus arrest (>5s) n= 16 (5%)

Sinus brady (>8s) n= 20 (7%)

AV block (>8s) n=29 (10%)

Page 13: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

1 s

Page 14: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

1.0

0.5

0.6

0.7

0.8

0.9

0.0

0 200 400 600 800

Time (days)

Eve

nts

Fre

e

NSVT

VTsustVF

AFib

Tachyarrhythmia: Time to first arrhythmia by ILR

Ventricular Fib. n=8 3% VT Sust. n=9 3%VT Non-sust. n=39 13% AFib n=95 32%

Page 15: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction
Page 16: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Conclusion Incidence of arrhythmias

27% had new onset atrial fibrillation

17% had high degree AV block or sinus bradyarrhythmia

17% had non-sust VT or VT/VF

Page 17: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Univariate analysisPredictors of cardiac death

N = 25 (9%)

HR p-value

AV block < 30 bpm 7.0 0.0004

Sinus brady < 30 bpm 5.8 0.004

Non sustained VT 3.4 0.025

Page 18: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Multivariate analysis

High-degree AV block was the only

independent predictor of cardiac death HR 4.8 [2.0-11.5] p < 0.001

Pre-specified arrhythmias were included as time dependent covariates in a multivariate Cox model.

Page 19: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Summary

CARISMA is the first study to report on long term arrhythmias and prognostics by an

implantable loop recorder in patients surviving an AMI with reduced left ventricular function

Page 20: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Conclusion

High-degree AV block

was the only independent predictor of

cardiac death

Page 21: CARISMA C ardiac A rrhythmias and RI sk  S tratification after M yocardial inf A rction

Future directions

The insertable ECG loop recorder is a diagnostic tool that should be considered to guide medical and

device therapy in patients surviving myocardial infarction